In addition, CD300a triggering has been linked to immune escape, and poor prognosis in certain cancers (e.g., glioblastoma [80], and diffuse large B cell lymphoma [49]), and may be stage specific in other models. Here, CD300A is linked to diffuse large B-cell lymphoma.